Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Scholar Rock Holding Corp (SRRK)

Scholar Rock Holding Corp (SRRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,859,614
  • Shares Outstanding, K 102,007
  • Annual Sales, $ 0 K
  • Annual Income, $ -246,290 K
  • EBIT $ -362 M
  • EBITDA $ -365 M
  • 60-Month Beta 0.67
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 18.77

Options Overview Details

View History
  • Implied Volatility 60.83% (-1.97%)
  • Historical Volatility 56.61%
  • IV Percentile 11%
  • IV Rank 12.06%
  • IV High 152.07% on 09/22/25
  • IV Low 48.31% on 07/21/25
  • Expected Move (DTE 8) 4.72 (10.01%)
  • Put/Call Vol Ratio 0.20
  • Today's Volume 162
  • Volume Avg (30-Day) 659
  • Put/Call OI Ratio 0.71
  • Today's Open Interest 17,852
  • Open Int (30-Day) 15,710
  • Expected Range 42.42 to 51.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.86
  • Number of Estimates 9
  • High Estimate -0.70
  • Low Estimate -0.98
  • Prior Year -0.60
  • Growth Rate Est. (year over year) -43.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.63 +16.04%
on 01/12/26
49.82 -5.38%
on 02/03/26
+4.96 (+11.76%)
since 01/09/26
3-Month
29.35 +60.61%
on 11/13/25
49.82 -5.38%
on 02/03/26
+16.35 (+53.10%)
since 11/11/25
52-Week
22.71 +107.57%
on 04/09/25
49.82 -5.38%
on 02/03/26
+10.11 (+27.30%)
since 02/11/25

Most Recent Stories

More News
Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

Scholar Rock (NASDAQ: SRRK) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026, before the financial markets open. The Company...

SRRK : 47.14 (-1.05%)
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 35,200 shares of its common stock to two newly hired employees,...

SRRK : 47.14 (-1.05%)
Scholar Rock Highlights 2026 Strategic Priorities

Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026 for the treatment of children and adults with spinal muscular atrophy (SMA)...

SRRK : 47.14 (-1.05%)
Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and...

SRRK : 47.14 (-1.05%)
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the “Company”), today announced that the company granted inducement equity awards covering an aggregate of 7,800 shares of its common stock to two newly hired employees,...

SRRK : 47.14 (-1.05%)
Scholar Rock to Present at Upcoming Investor Conferences

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and...

SRRK : 47.14 (-1.05%)
Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Completed constructive and collaborative in-person Type A meeting with U.S. Food and Drug Administration (FDA) on November 12 th for apitegromab biologics license application (BLA)...

SRRK : 47.14 (-1.05%)
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 30,000 shares of its common stock to 1 newly hired employee, consisting...

SRRK : 47.14 (-1.05%)
3 Beaten-Down Stocks With Rebound Potential This Earnings Season

These firms present at least a modest risk/reward profile, but could be preparing for a share price turnaround depending upon how earnings season plays out.

GLOB : 55.47 (-7.92%)
NICE : 110.97 (-2.29%)
SRRK : 47.14 (-1.05%)
Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and...

SRRK : 47.14 (-1.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company's product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge,...

See More

Key Turning Points

3rd Resistance Point 49.89
2nd Resistance Point 48.89
1st Resistance Point 48.01
Last Price 47.14
1st Support Level 46.13
2nd Support Level 45.13
3rd Support Level 44.25

See More

52-Week High 49.82
Last Price 47.14
Fibonacci 61.8% 39.46
Fibonacci 50% 36.26
Fibonacci 38.2% 33.07
52-Week Low 22.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar